Open Medicine Foundation is turning ten years old! Please join us in celebrating a decade of leading research and delivering hope.
People with Chronic Complex Diseases deserve the right to live full, productive lives.
on Charity Navigator!
OMF’s score of 100 serves as an indicator of trust, demonstrating our longstanding commitment to ensuring accountability, transparency, and measures of financial health, including stability, efficiency and sustainability.
OMF ACCELERATES RESEARCH ACROSS THE GLOBE
Since our inception in 2012, Open Medicine Foundation (OMF) has raised over $37 million to fund open and collaborative research and improve health care for millions suffering with multi-system chronic, complex diseases (msCCD). Our disease focus includes Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS), Long COVID, Post-Treatment Lyme Disease, and Fibromyalgia.
We have facilitated and funded the establishment of 7 collaborative centers across the globe, in 4 countries and 3 continents. These centers are dedicated to diagnosing, treating, and ultimately curing these related chronic, complex diseases.
Open Medicine Foundation is a US based global nonprofit, with an affiliate organization in Canada (OMF Canada) and a foreign branch in Australia (OMF Australia Ltd). Our 19 member Scientific Advisory Board is world renowned and includes two Nobel laureates and 6 National Academy of Sciences members.
OMF Supported Collaborative Centers
at Stanford
Ronald W. Davis, PhD
Director
Innovative, collaborative, multi-disciplinary research
Wenzhong Xiao, PhD
Co-Director
David Systrom, MD
Co-Director
Clinical and scientific mechanistic studies towards discovering new treatments
at Uppsala, Sweden
Jonas Bergquist, MD, PhD
Director
Research for biomarkers in body and brain
Alain Moreau, PhD
Director
Clinical and scientific intervention studies
Chris Armstrong, PhD
Director
Precision research program
Wenzhong Xiao, PhD
Director
From data to disease mechanism and treatments
at Bateman Horne Center
Lucinda Bateman, MD
Medical Education Director
A global initiative to increase access to knowledgeable healthcare providers and improve patient care.
Long Covid TO ME/CFS RESEARCH PLAN
The current COVID-19 pandemic offers an unprecedented opportunity to understand how a viral infection may convert to ME/CFS in some patients.
The six Collaborative Research Centers have begun a unique, extensive, in-depth longitudinal molecular study following COVID-19 patients. Their shared goal is to determine the pathways involved in maintaining long-term symptoms in some patients, possibly converting to ME/CFS. They seek to learn about these pathways so as to develop biomarkers, novel drug targets, new treatment, and prevention strategies.
OMF Scientific Advisory Board
19 world-renowned scientists
2 Nobel laureates
6 National Academy
of Sciences members
Research Interviews
View our latest news
LAST DAY this year to TRIPLE your impact toward treatment trials!
Support small ME/CFS treatment trials: Nov. 29, 2022 is the LAST DAY this year to get your donation to OMF TRIPLED!
OMF Awarded Research Grants from The Patient-Led Research Collaborative!
OMF Awarded Research Grants fromThe Patient-Led Research Collaborative! Big news: The Patient-Led Research Collaborative has announced $4.8 million in biomedical research awards for ME/CFS,
Ron Davis: New Neutrophil Study!
A new study from Ron Davis and Stanford colleagues aims to identify neutrophil abnormalities that are unique to ME/CFS patients.
Join our Fight to Ignite ME / CFS Research
Across the Globe!
OMF’s international community —
United by a shared commitment to find answers to end ME / CFS and related multi-system chronic, complex diseases (msCCD).
The Faces of ME / CFS
What is ME / CFS?
Join OMF to Find A Cure
Take Action Now!
Please help us expand our research efforts across the globe.
Every donation brings us closer to a fully funded research effort and the answers we all seek.
"Our donors want to stop millions from suffering and have come to expect research with impeccable credibility. The time is now to attract the kind of serious investment that will speed up our search for a cure and end these debilitating diseases."
